AIDX
20/20 Biolabs, Inc. (NASDAQ)
Healthcare — Medical Devices
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
Price History
Fundamentals
| Market Cap | $6.73M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-0.49 |
| Dividend Yield | - |
| Profit Margin | -279.13% |
| Revenue Growth | -36.20% |
| ROE | -241.59% |
| Debt/Equity | 33.57 |
| Recommendation | None |
| Analyst Target | $5.00 |
| Analysts | 1 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 36.4 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $50.00 |
| 52-Week Low | $0.52 |
| 50-Day Avg | $1.14 |
| 200-Day Avg | $2.22 |
| Avg Volume | 736.8K |
| Volume | 287.4K |
Performance Analysis
NEUTRALAIDX presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jun 30, 2026 21:07 UTC
Back to Screener Export Report